Implications of epigenetic modulation for novel treatment approaches in patients with schizophrenia

Página do item simplificado
dc.contributor.authorCha, Danielle S.
dc.contributor.authorKudlow, Paul A.
dc.contributor.authorBaskaran, Anusha
dc.contributor.authorMansur, Rodrigo B. [UNIFESP]
dc.contributor.authorMcIntyre, Roger S.
dc.contributor.institutionUniv Hlth Network
dc.contributor.institutionUniv Toronto
dc.contributor.institutionQueens Univ
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:35:14Z
dc.date.available2016-01-24T14:35:14Z
dc.date.issued2014-02-01
dc.description.abstractSchizophrenia is a heterogeneous and complex mental disorder with high rates of disability, non-recovery, and relapse. the primary pharmacological treatments for schizophrenia are antipsychotics. Notwithstanding the efficacy of antipsychotics in ameliorating positive symptoms and reducing relapse rates, cognitive deficits and negative symptoms are not sufficiently treated with available pharmaceutical agents. Moreover, schizophrenia is associated with consistent, replicable, and clinically significant deficits in cognition. the importance of cognitive deficits in schizophrenia is emphasized by reports indicating that the severity of cognitive deficits is predictive of treatment compliance, adherence, and risk of relapse among first-episode individuals. Taken together, this review highlights epigenetic modulations involving histone deacetylase (HDAC) inhibitors as a potential avenue for novel treatment toward improvements in cognition and functional outcomes in patients with schizophrenia. the combination of epigenetic modulation with pharmacological interventions that engage multiple disparate physiological systems implicated in schizophrenia are discussed, and may represent a more effective strategy in ameliorating cognitive deficits and mitigating symptoms for improved functionality. (C) 2013 Elsevier B.V. All rights reserved.en
dc.description.affiliationUniv Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON M5T 2S8, Canada
dc.description.affiliationUniv Toronto, Inst Med Sci, Toronto, ON, Canada
dc.description.affiliationUniv Toronto, Dept Psychiat, Toronto, ON, Canada
dc.description.affiliationQueens Univ, Ctr Neurosci Studies, Kingston, ON, Canada
dc.description.affiliationUniversidade Federal de São Paulo, Interdisciplinary Lab Clin Neurosci LINC, Dept Psychiat, São Paulo, Brazil
dc.description.affiliationUniv Toronto, Dept Pharmacol, Toronto, ON, Canada
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Interdisciplinary Lab Clin Neurosci LINC, Dept Psychiat, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent481-486
dc.identifierhttp://dx.doi.org/10.1016/j.neuropharm.2013.08.038
dc.identifier.citationNeuropharmacology. Oxford: Pergamon-Elsevier B.V., v. 77, p. 481-486, 2014.
dc.identifier.doi10.1016/j.neuropharm.2013.08.038
dc.identifier.issn0028-3908
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/37381
dc.identifier.wosWOS:000330490000050
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofNeuropharmacology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.subjectSchizophreniaen
dc.subjectEpigeneticen
dc.subjectCognitionen
dc.subjectTreatmenten
dc.subjectAntipsychoticen
dc.subjectHistone modificationen
dc.subjectHistone acetylaseen
dc.subjectHistone deacetylaseen
dc.titleImplications of epigenetic modulation for novel treatment approaches in patients with schizophreniaen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Outras produções